Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410830 | 0.81 | ALDH1A1 (0.56) | NPSR1SMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL12145458 | 0.73 | KDM4E (0.48) | SMN1; SMN2ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL13062478 | 0.71 | ALDH1A1 (0.31) | SMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL31630179 | 0.67 | EPHX1 (0.57) | NPSR1SMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL7039814 | 0.66 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL7035637 | 0.63 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL7040734 | 0.63 | CFD (0.50) | NPSR1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL13014504 | 0.63 | GAA (0.41) | NPSR1SMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL25001923 | 0.62 | ALDH1A1 (0.59) | NPSR1SMN1; SMN2ALDH1A1MAPTHPGD | |
| Thiophanate Methyl SCHEMBL29422247 | 0.62 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | NPSR1 172/4885SMN1; SMN2 3274/4885ALDH1A1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.